Summary of Key Points Core Viewpoint - The company *ST Songfa (603268) has signed a significant contract for the construction of two VLCC supertankers, which is expected to positively impact its future performance despite potential risks associated with contract execution [1]. Trading Information - On January 22, *ST Songfa closed at 86.82 yuan, down 2.65%, with a turnover rate of 1.85% and a trading volume of 23,000 shares, amounting to a total transaction value of 201 million yuan [1]. - On the same day, the main funds experienced a net outflow of 39.593 million yuan, accounting for 19.66% of the total transaction value [1]. - Retail investors saw a net inflow of 9.0246 million yuan, representing 4.48% of the total transaction value [1]. Company Announcements - The subsidiary of Guangdong Songfa Ceramics Co., Ltd., Hengli Shipbuilding (Dalian) Co., Ltd., has signed a contract for the construction of two 30.6 million-ton VLCC supertankers, with a total contract value of approximately 200-300 million USD, expected to be delivered in the second half of 2028 [1]. - The contract is with a Singapore-based company, Eastern Pacific Shipping Pte. Ltd., and there is no related party relationship between the two parties [1]. - The long execution period of the contract may be influenced by market conditions, raw material prices, and exchange rates, which introduces execution risks [1].

Group 1: Company Fundraising and Investment - Company plans to use 500 million yuan of raised funds to increase capital in its wholly-owned subsidiaries for the implementation of a DRAM investment project [1] - Zhuhai Hengqin Chip Storage Co., Ltd. will receive 30 million yuan, and Hefei Chip Storage Co., Ltd. and Xi'an Chip Storage Co., Ltd. will receive 50 million yuan and 30 million yuan respectively for the DRAM project [1] Group 2: Profit Forecasts and Turnarounds - Yiling Pharmaceutical expects a net profit of 1.2 billion to 1.3 billion yuan in 2025, recovering from a loss of 725 million yuan in the previous year [2] - Liard anticipates a net profit of 300 million to 380 million yuan in 2025, compared to a loss of 889 million yuan last year, driven by a new strategic cycle focusing on AI [2] - Daming City forecasts a net profit of 140 million to 165 million yuan in 2025, recovering from a loss in the previous year, aided by reduced asset impairment losses [3] - Guanghua Technology expects a net profit of 85 million to 120 million yuan in 2025, recovering from a loss of 205 million yuan last year, due to expansion in specialized chemicals and PCB sectors [3] - Boteng Co. anticipates a net profit of 80 million to 105 million yuan in 2025, recovering from a loss of 288 million yuan, supported by operational efficiency improvements [4] - Shiyida expects a net profit of 31 million to 46 million yuan in 2025, recovering from a loss of 2.34 million yuan last year, driven by business development and cost control [4] - Guochuang High-tech forecasts a net profit of 16 million to 24 million yuan in 2025, recovering from a loss of 49 million yuan, aided by improved receivables management [5][6] Group 3: Share Buybacks - Hengyi Petrochemical plans to repurchase shares with a total fund of no less than 500 million yuan and no more than 1 billion yuan, with a maximum price of 15 yuan per share [7] - Yunyi Electric plans to repurchase shares with a total fund of no less than 100 million yuan and no more than 150 million yuan, with a maximum price of 17 yuan per share [7] - Xidian Pharmaceutical intends to repurchase shares with a total fund of no less than 25 million yuan and no more than 50 million yuan, with a maximum price of 42 yuan per share [7] Group 4: Performance Highlights - Te Yi Pharmaceutical expects a net profit of 70 million to 90 million yuan in 2025, a growth of 241.55% to 339.13% year-on-year [8] - Xingqi Eye Medicine anticipates a net profit of 662 million to 749 million yuan in 2025, a growth of 95.82% to 121.56% year-on-year [8] - Tianhe Co. forecasts a net profit of 41 million to 60 million yuan in 2025, a growth of 84.35% to 169.78% year-on-year [8] - Ruichuang Micro-Nano expects a net profit of approximately 1.1 billion yuan in 2025, a 93% increase year-on-year [9] - Zhongyuan Co. anticipates a net profit of 139 million to 158 million yuan in 2025, a growth of 80% to 105% year-on-year [9] Group 5: Important Corporate Developments - Aolaide has received acceptance for its application to issue securities on the Science and Technology Innovation Board [14] - *ST Songfa's subsidiary signed contracts for the construction of two VLCC super-large oil tankers, expected to positively impact future performance [15] - Chongda Technology's subsidiary signed an investment agreement for a 1 billion yuan IC packaging project in Jiangsu Province [15] - Yinglian Co. signed a strategic agreement with LG Chem to establish a joint laboratory for innovative materials in lithium battery applications [16]

Group 1 - Huakang Clean announced it is the first candidate for the bid of the Wuhan First Hospital expansion project with a bid amount of 54.88 million yuan and a construction period of 120 days [1] - Hualing Steel's subsidiary plans to invest 449.88 million yuan in a major overhaul project for its coking plant, aiming to address aging issues and restore production capacity over a 19-month construction period [2] - Yinjia Technology expects a net loss of 140 million to 110 million yuan for 2025, compared to a loss of 129 million yuan in the previous year [3] Group 2 - Guochuang High-tech forecasts a net profit of 16 million to 24 million yuan for 2025, recovering from a loss of 58.52 million yuan in the previous year [4] - Shiyi Da anticipates a net profit increase of 31 million to 46 million yuan for 2025, turning around from a loss of 23.41 million yuan last year [5] - Lijun Co. expects a net profit of 48 million to 66 million yuan for 2025, representing a decline of 45.05% to 60.03% compared to the previous year [7] Group 3 - Xindian Pharmaceutical plans to repurchase shares worth 25 million to 50 million yuan for employee stock ownership plans or equity incentives, with a maximum repurchase price of 42 yuan per share [6] - Jingchen Co. has set the initial transfer price for its shares at 82.85 yuan per share, with a total of 13.1 million shares to be transferred to 28 institutional investors [8] - Zejing Pharmaceutical received approval for clinical trials of its innovative cancer immunotherapy drug ZG005 in combination with platinum-based chemotherapy for advanced nasopharyngeal and esophageal squamous cell carcinoma [9] Group 4 - Xingqi Eye Medicine expects a net profit of 662 million to 749 million yuan for 2025, marking a growth of 95.82% to 121.56% compared to the previous year [10] - Liancheng Precision anticipates a net loss of 12 million to 17 million yuan for 2025, reducing its loss from 37.96 million yuan in the previous year [11] - Beidou Star expects a net loss of 230 million to 290 million yuan for 2025, improving from a loss of 350 million yuan last year [13] Group 5 - Qing Shan Paper's affiliate won a bid for a wastewater treatment project worth 51.9 million yuan [15] - Yiling Pharmaceutical forecasts a net profit of 1.2 billion to 1.3 billion yuan for 2025, recovering from a loss of 725 million yuan in the previous year [16] - Huahai Pharmaceutical received a drug registration certificate for its product used in treating depression and obsessive-compulsive disorder [23] Group 6 - Nanjing Panda expects a net profit of 10 million to 15 million yuan for 2025, turning around from a loss of 189 million yuan last year [40] - Rui Sheng Intelligent anticipates a net profit of 33.92 million to 38.40 million yuan for 2025, representing a growth of 112% to 140% compared to the previous year [41] - Jiechang Drive expects a net profit of 395 million to 437 million yuan for 2025, with a growth of 40% to 55% compared to the previous year [43]

Core Viewpoint - *ST Songfa (603268) has signed contracts for the construction of two 30.6 million-ton VLCC super-large crude oil tankers, which is expected to positively impact the company's future performance [1] Group 1: Stock Performance - As of January 22, 2026, *ST Songfa closed at 86.82 yuan, down 2.65% from the previous trading day, with a total market value of 84.283 billion yuan [1] - The stock opened at 89.25 yuan, reached a high of 89.82 yuan, and a low of 86.22 yuan, with a trading volume of 201 million yuan and a turnover rate of 1.85% [1] Group 2: Contract Details - The contracts for the two VLCC tankers were signed with Eastern Pacific Shipping Pte. Ltd., a Singapore-based company, and the total contract value is approximately 200-300 million USD [1] - The delivery of the tankers is expected in the second half of 2028, and the contract is classified as a routine operational contract, not requiring board or shareholder approval [1] - The long contract execution period may be influenced by market conditions, raw material prices, and exchange rates, which introduces performance risks [1]

Core Viewpoint - *ST Songfa has signed contracts for the construction of two 306,000-ton VLCC super-large crude oil tankers, with a total contract value of approximately $200-300 million, expected to be delivered in the second half of 2028 [1] Group 1 - The contracts were signed by the subsidiary Hengli Shipbuilding (Dalian) Co., Ltd [1] - The vessels are classified as Very Large Crude Carriers (VLCC) [1] - The delivery timeline for the vessels is set for the second half of 2028 [1]

(本文来自第一财经) *ST松发公告，下属公司恒力造船（大连）有限公司2艘30.6万吨VLCC超大型原油运输船建造合同于近 日签约生效，合同金额合计约2-3亿美元。合同履约期自签约至船舶交付，采用美元按履约进度分期支 付，2028年下半年相继交付。交易对方为Eastern Pacific Shipping Pte. Ltd.旗下单船公司。 ...

证券代码：603268 证券简称：*ST松发 公告编号：2026-009 广东松发陶瓷股份有限公司 关于下属公司签订日常经营重大合同的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次签署的相关合同系日常经营性合同，公司与交易对方不存在关联关系，所 涉及的交易不构成关联交易，根据《股票上市规则》之规定，公司本次签署日常交 易相关合同无需经公司董事会、股东会审议。 二、合同主要内容 是否需要履行审议程序：本次签署的相关合同系日常经营性合同，公司与 交易对方不存在关联关系，所涉及的交易不构成关联交易，根据《上海证 券交易所股票上市规则》（以下简称"《股票上市规则》"）之规定，公 司本次签署日常交易相关合同无需经公司董事会、股东会审议。 特别风险提示：由于合同履行期较长，合同履行可能受到航运与船舶市场 变化、客户需求、原材料价格波动、汇率波动等因素影响，敬请广大投资 者注意投资风险。 1、 合同标的：2艘30.6万吨VLCC超大型原油运输船 2、 合同金额：本次标的合同金额合计约2-3亿美元。本次金额达到了《 ...

每经AI快讯，1月22日，*ST松发（603268）公告，公司下属公司恒力造船（大连）有限公司近日与 EasternPacificShippingPte.Ltd.旗下单船公司签订2艘30.6万吨VLCC超大型原油运输船建造合同，合同金 额合计约2.00亿至3.00亿美元；合同履约期限自签约生效至2028年下半年相继交付；支付方式为美元分 期支付；争议解决方式为伦敦海事仲裁员协会（LMAA）伦敦仲裁。 ...

格隆汇1月22日丨*ST松发(603268.SH)公布，公司下属公司恒力造船（大连）有限公司（简称"恒力造 船"）2艘船舶建造合同于近日签约生效，合同标的：2艘30.6万吨VLCC超大型原油运输船，本次标的合 同金额合计约2-3亿美元。 ...

松发股份公告称，下属公司恒力造船近日签约生效2艘船舶建造合同，标的为2艘30.6万吨VLCC超大型 原油运输船，合同金额约2 - 3亿美元。合同履约期自签约至船舶交付，采用美元按履约进度分期支付， 2028年下半年相继交付。交易对方是Eastern Pacific Shipping Pte.Ltd.旗下单船公司，资信良好、具备履 约能力。合同预计对公司业绩有积极影响，但履行期长，受多种因素影响，总体风险可控。 ...